Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maxigesic IV Safety and Tolerability in Postoperative Pain
NCT04005755Phase 3Completed
- Sponsor
- AFT Pharmaceuticals
- Start
- Jul 2019
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of Combogesic IV in postoperative pain, sponsored by AFT Pharmaceuticals. Primary endpoint: Incidence of Treatment-Emergent Adverse Events. Started Jul 2019; status: completed.
02
Drugs
Combogesic IV
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT04005755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04005755.